AMRN : Summary for Amarin Corporation plc - Americ - Yahoo Finance

U.S. Markets closed

Amarin Corporation plc (AMRN)


NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
2.95+0.07 (+2.43%)
At close: 4:00PM EST
People also watch
ARNAARIAGALEACHNOREX
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Previous Close2.88
Open2.91
Bid2.85 x 3000
Ask3.95 x 200
Day's Range2.90 - 2.97
52 Week Range2.56 - 3.65
Volume1,453,596
Avg. Volume2,093,095
Market Cap794.08M
Beta1.75
PE Ratio (TTM)-6.81
EPS (TTM)N/A
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • GlobeNewswire2 days ago

    Amarin Announces Debt Restructuring and Related Private Placement of Exchangeable Senior Notes

    BEDMINSTER, N.J. and DUBLIN, Ireland, Jan. 20, 2017-- Amarin Corporation plc announced today that it and its wholly owned subsidiary, Corsicanto II Designated Activity Company, have entered into separate, ...

  • Reuters3 days ago

    FDA issues draft guidance to better medical product labeling

    The U.S. health regulator issued draft guidance, recommending ways to communicate promotional materials and additional information that is not on the label of medical products. The U.S. Food and Drug Administration typically determines what information goes on the labels of medical drugs and devices, after evaluating whether the product is safe and effective for the proposed indication. If a firm communicates information, including on promotional material, that has not been evaluated by the regulator, but appears to be FDA-ratified, then it could lead to misbranding, and could subject firms to enforcement action if the representations or suggestions are considered false or misleading.

  • More Innovation, Less Regulation: 2 Biotech Stocks That Could Soar in 2017
    Motley Fool10 days ago

    More Innovation, Less Regulation: 2 Biotech Stocks That Could Soar in 2017

    Trump appears ready to deal a major blow to the FDA's regulatory powers. Here are two stocks that would benefit enormously from such a move.